Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer

Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors. Cytoreductive Surgery (CRS) combined with chemotherapy is the standard treatment for patients with advanced ovarian cancer. However, most of the ovarian cancer is stage Ⅲ and above, and there may be a certain degree of organ metastasis. Preclinical studies have found that the stress of melanoma block beta adrenergic signals in mice, which USES beta blockers, checkpoint will enh

Trial Details

NCT ID

NCT07125391

Phase

PHASE2

Sponsor

Bai-Rong Xia

Status

RECRUITING

Cancer Type

High-Grade Serous Ovarian Cancer

Interventions

Propranolol Hydrochloride
Paclitaxel liposome
Carboplatin

Locations (sample)

Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

Written informed consent was obtained before any trial-related procedures were performed.
Women, 18 to 75 years old;
FIGO stage for stage III or IV, including not surgery in patients with stage III or IV beginning for ovarian cancer; Histopathology confirmed high-…
According to the response evaluation criteria in 1.1 (RECIST1.1) definition, patients must have a measurable lesions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →